Navigation Links
Oramed Pharmaceuticals to Present Oral Insulin Phase 2A Trial Results at the Upcoming Annual Meeting of the ADA (June 5-9, New Orleans, LA)
Date:3/25/2009

JERUSALEM, March 25 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB) (http://www.oramed.com), a developer of oral delivery systems, announced today that it has been selected to present the results from the study, entitled, "Open Label Study to Assess the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Oral Insulin Formulations in Subjects with Type 2 Diabetes (T2DM)" at the upcoming 69th Annual American Diabetes Association's Scientific Sessions Conference in New Orleans. The presentation will highlight the successful results from its oral insulin trials on type 2 diabetes patients completed in August 2008.

An abstract will also be printed in the Scientific Sessions Abstract Book, the June 2009 supplement to the journal Diabetes.

"Oramed is pleased to present this poster featuring the results from our phase 2A study of ORMD-0801 on type 2 diabetes patients and to share the information with our colleagues," said Nadav Kidron, Oramed CEO. "As we indicated at the completion of the study, the trial demonstrated that the oral insulin capsule had a good safety profile and was well tolerated and effective in lowering blood glucose levels in patients with type 2 diabetes."

Oramed's poster has been assigned presentation number 434-P Clinical Therapeutics/New Technology - Insulin Delivery Systems and is available for viewing throughout the conference. A representative of the company will be available to answer questions on Monday, June 8 from 12-2 PM at the Morial Convention Center.

For more information about the ADA and the upcoming conference, please visit http://professional.diabetes.org

Forward-looking statements

Some of the statements contained in this press release are forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for our product candidates; competition from other pharmaceutical or biotechnology companies; and the company's ability to obtain additional funding required to conduct its research, development and commercialization activities. Please refer to the company's filings with the Securities and Exchange Commission for a comprehensive list of risk factors that could cause actual results, performance or achievements of the company to differ materially from those expressed or implied in such forward looking statements. The company undertakes no obligation to update or revise any forward-looking statements.

    Company and Investor Relation Contacts:
    Oramed Pharmaceuticals
    Tara Horn
    USA: +1-646-240-4193
    Int'l:: +972-54-334-318
    Office: +972-2-566-0001
    Email: Tara@oramed.com


'/>"/>
SOURCE Oramed Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Oramed Pharmaceuticals to Hold Conference Call on August 6 to Present Results of Phase 2A Oral Insulin Capsule Clinical Trials
2. Oramed Pharmaceuticals Announces Successful Phase 2A Clinical Trial of its Oral Insulin Capsule
3. Oramed Pharmaceuticals Chosen to Present Oral Insulin Trial Results at EASD Conference (September 7-11, Rome)
4. Oramed Pharmaceuticals Launches GLP1-Analog Program, Based on its Proprietary Drug Delivery Platform
5. Oramed Pharmaceuticals Commences Phase 2A Trials of its Oral Insulin Capsule on Type 1 Diabetics
6. /K I L L K I L L K I L L -- Oramed Pharmaceuticals Inc./
7. Oramed Pharmaceuticals Launches Phase 1A Trials of its Insulin Suppository
8. Oramed Pharmaceuticals Chosen to Present Results of GLP-1 Analog Enteral Administration Study at the Diabetes Technology Societys Eighth Annual Meeting (November 13-15, 2008; Bethesda, Maryland)
9. Oramed Pharmaceuticals Completes Proof of Concept Study of Insulin Suppository
10. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)...  Patients in Alabama seeking prostate ... no longer have to travel out of state. Vituro ... Urology Centers of Alabama to provide a total prostate ... patients. Alabama is known ... prostate cancer using many different modalities. They are the largest ...
(Date:2/5/2016)... , Feb. 5, 2016 Aethlon Medical, Inc. ... , Chairman and CEO, will be presenting at Source Capital ... New York, NY at 2:15 p.m. ET on ... an Immunotherapy Panel discussion taking place at 3:15 p.m. ET. ... replay approximately one hour after the conclusion of the live ...
(Date:2/5/2016)... 5, 2016 Dehaier Medical Systems Ltd. ... "Company"), which develops, markets and sells medical devices ... China and international markets, today announced ... to concentrate the Company,s resources to develop its ... and to focus more on its major businesses. ...
Breaking Medicine Technology:
(Date:2/5/2016)... New York, New York (PRWEB) , ... February 05, 2016 , ... ... in gym use and find themselves having to wait longer to access the treadmills. ... on their New Year’s resolutions to lose weight and get in shape by joining ...
(Date:2/5/2016)... Atlanta, Georgia (PRWEB) , ... February 05, 2016 , ... ... pleased to announce their 2nd Annual No Cost Dental Day to individuals in need. ... 4pm. The purpose of this No Cost Dental Day is to provide dental care ...
(Date:2/5/2016)... ... ... and wellness is a topic that should concern all Americans; however, it tends to ... are a severe form of a headache and often are accompanied by many various ... their worst enemy, the feeling can last for many hours and be totally debilitating. ...
(Date:2/5/2016)... ... February 05, 2016 , ... –This week, Atascadero water heater company ... a tankless water heater. To view the report, click here or see ... While each has their pros and cons, the type chosen is almost entirely up ...
(Date:2/4/2016)... ... February 04, 2016 , ... American Addiction ... and the start of Project HoldSpace. Through the partnership, the two organizations seek ... of youth between the ages of 13 and 18. Currently focused on Ohio ...
Breaking Medicine News(10 mins):